2026-06-14T05:06:46Zhttps://repisalud.isciii.es/rest/oai/request

oai:repisalud.isciii.es:20.500.12105/254602025-12-18T12:56:35Zcom_20.500.12105_2052com_20.500.12105_2051com_20.500.12105_15322col_20.500.12105_19608col_20.500.12105_16967

00925njm 22002777a 4500 dc Vega-Piris, Lorena author Galindo Carretero, Silvia author Mayordomo, José Luis author Rumayor-Zarzuelo, Mercedes Belén author Álvarez Río, Virginia author Gallardo García, Virtudes author García Vázquez, Miriam author García Rodríguez, María Del Carmen author Basile, Luca author López González-Coviella, Nieves author Barranco Boada, Maria Isabel author Pérez-Martínez, Olaia author Lameiras Azevedo, Ana author Quiñones-Rubio, Carmen author Giménez Duran, Jaume author Fernández Ibáñez, Ana author García Rivera, María Victoria author Ramos Marín, Violeta author Castrillejo, Daniel author Voloria Raymundo, Luis Javier author Larrauri, Amparo author Monge Corella, Susana author SARI Sentinel Surveillance Group author 2024-11 Introduction: Our aim was to estimate the risk of pneumonia, admission to intensive care unit (ICU) or death in individuals ≥65 years old admitted to hospital with RSV, compared to influenza or COVID-19. Methods: We included hospitalised patients from Severe Acute Respiratory Infection Surveillance in Spain between 2021-2024, aged ≥65 years, laboratory confirmed for RSV, influenza or SARS-CoV-2. Using a binomial regression with logarithmic link, we estimated the relative risk (RR) of pneumonia, ICU admission and in-hospital mortality, in patients with RSV compared to influenza or SARS-CoV-2, adjusting for age, sex, season and comorbidities. We stratified the estimates by vaccination status for influenza or SARS-CoV2. Results: Among patients unvaccinated for influenza or SARS-CoV-2, those with RSV had similar or lower risk of pneumonia [vs. influenza: RR= 0.91 (95% Confidence Interval: 0.72-1.16); vs. SARS-CoV-2: 0.81 (0.67-0.98)], ICU admission [vs. influenza: 0.93 (0.41-2.08); vs. SARS-CoV-2: 1.10 (0.61-1.99)] and mortality [vs. influenza: 0.64 (0.32-1.28); vs. SARS-CoV-2: 0.56 (0.30-1.04)]. Among the vaccinated, results were largely similar except for a higher risk of ICU admission with RSV [vs. influenza: 2.13(1.16-3.89); vs. SARS-CoV-2: 1.83 (1.02-3.28)] CONCLUSIONS: RSV presented similar or lower intrinsic severity than influenza or SARS-CoV2. Among vaccinated patients, RSV was associated to higher ICU-admission, suggesting the potential for preventive RSV vaccination. J Infect. 2024 Nov;89(5):106292. 10.1016/j.jinf.2024.106292 1532-2742 0163-4453 The Journal of infection 39341402 https://hdl.handle.net/20.500.12105/25460 ICU admission Influenza Mortality Pneumonia SARS-CoV2 Severe acute respiratory infection Syncytial respiratory virus Vaccination Severity of respiratory syncytial virus compared with SARS-CoV-2 and influenza among hospitalised adults ≥65 years.